Foresite Capital Management IV, LLC — Q4 2024 13F-HR

← Foresite Capital Management IV, LLC

Q4 2024 · 13F-HR

Foresite Capital Management IV, LLCholdings as filed

Filed 2025-02-14 · accession 0001104659-25-013923

$108.8M

Reported value

Positions

2024-12-31

Period end

View analyzed profile →PRO

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
N69605108	PHVS	Pharvaris N.V.	$84.3M	77.5%	4,397,881	Common	SOLE
50127T109	KURA	Kura Oncology, Inc.	$15.0M	13.8%	1,726,882	Common	SOLE
55083R104	—	Lyell Immunopharma, Inc.	$5.3M	4.90%	8,325,000	Common	SOLE
75943R102	RLAY	Relay Therapeutics Inc.	$4.1M	3.79%	1,000,000	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.